leadf
logo-loader
viewANGLE PLC

ANGLE notes USC study highlighting advantages of Parsortix over standard tissue biopsy

The biopsy firm said the study demonstrated “key capabilities of Parsortix for metastatic breast cancer”, the focus of its pending submission to the US Food & Drug Administration

ANGLE PLC - ANGLE notes USC study highlighting advantages of Parsortix over standard tissue biopsy

ANGLE PLC (LON:AGL) said the results of a new study from the University of Southern California (USC), published in the International Journal of Molecular Sciences, have highlighted the “key advantages” of its Parsortix liquid biopsy system compared to a standard of care tissue biopsy.

The AIM-listed firm said in addition to the known advantages of a non-invasive, repeatable and low cost procedure, the USC study showed that “potential actionable therapeutic targets” were found in the Parsortix biopsy that were missed in the tissue biopsy of a single metastatic site.

READ: ANGLE hails major progress, targets regulator submissions in third quarter of 2020

The study investigated concordance between cancer cells obtained from the blood test (circulating tumour cells - CTCs - harvested by Parsortix) and those obtained from the metastatic tissue biopsy across 4,600 medically relevant genes.

ANGLE said the study demonstrated “key capabilities of Parsortix for metastatic breast cancer”, the focus of its submission to the US Food and Drug Administration (FDA) which is planned for the third quarter of 2020.

"This study highlights both practical advantages of the Parsortix liquid biopsy in allowing non-invasive repeat biopsies in metastatic breast cancer and technical advantages in identifying actionable therapeutic targets that may be missed when relying on a single site tissue biopsy", Julie Lang, associate professor at USC’s Keck School of Medicine said in a statement.

ANGLE’s founder and chief executive Andrew Newland added: "The demonstration of advanced gene expression analysis techniques on CTCs harvested by Parsortix highlights an important potential clinical use of the Parsortix system once FDA clearance for metastatic breast cancer has been secured."

ANGLE shares rose 1.6% to 56.9p in early deals on Monday.

Quick facts: ANGLE PLC

Price: 51 GBX

AIM:AGL
Market: AIM
Market Cap: £88.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18

2 min read